{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:54:31Z","timestamp":1790790871309,"version":"4.1.0"},"reference-count":50,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T00:00:00Z","timestamp":1605398400000},"content-version":"unspecified","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1A2C2004530"],"award-info":[{"award-number":["2020R1A2C2004530"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1C1C1008212"],"award-info":[{"award-number":["2020R1C1C1008212"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1C1C1010722"],"award-info":[{"award-number":["2020R1C1C1010722"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,10,25]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Peritoneal carcinomatosis (PC) is a common and devastating manifestation of colon cancer and refractory to conventional anticancer therapeutics. During the peritoneal dissemination of colon cancer, peritoneal immunity is nullified by various mechanisms of immune evasion. Here, we employed the armed oncolytic vaccinia virus mJX-594 (JX) to rejuvenate the peritoneal antitumor immune responses in the treatment of PC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>PC model of MC38 colon cancer was generated and intraperitoneally treated with JX and\/or anti-programmed cell death protein 1 (PD-1) antibody. The peritoneal tumor burden, vascular leakage, and malignant ascites formation were then assessed. Tumors and peritoneal lavage cells were analyzed by flow cytometry, multiplex tissue imaging, and a NanoString assay.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>JX treatment effectively suppressed peritoneal cancer progression and malignant ascites formation. It also restored the peritoneal anticancer immunity by activating peritoneal dendritic cells (DCs) and CD8<jats:sup>+<\/jats:sup> T cells. Moreover, JX selectively infected and killed peritoneal colon cancer cells and promoted the intratumoral infiltration of DCs and CD8<jats:sup>+<\/jats:sup> T cells into peritoneal tumor nodules. JX reinvigorates anticancer immunity by reprogramming immune-related transcriptional signatures within the tumor microenvironment. Notably, JX cooperates with immune checkpoint inhibitors (ICIs), anti-programmed death-1, anti-programmed death-ligand 1, and anti-lymphocyte-activation gene-3 to elicit a stronger anticancer immunity that eliminates peritoneal metastases and malignant ascites of colon cancer compared with JX or ICI alone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Intraperitoneal immunotherapy with JX restores peritoneal anticancer immunity and potentiates immune checkpoint blockade to suppress PC and malignant ascites in colon cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-000857","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T16:25:28Z","timestamp":1605543928000},"page":"e000857","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":53,"title":["Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer"],"prefix":"10.1136","volume":"8","author":[{"given":"Yu Seong","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Biomedical Science, CHA University, Seongnam, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Suk","family":"Lee","sequence":"additional","affiliation":[{"name":"Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Woo","family":"Kim","sequence":"additional","affiliation":[{"name":"Kyung Hee University Gangdong Hospital, Gangdong-gu, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Joon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, CHA University, Seongnam, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Yang","sequence":"additional","affiliation":[{"name":"Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Jung","family":"Kong","sequence":"additional","affiliation":[{"name":"Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ning","sequence":"additional","affiliation":[{"name":"SillaJen Biotherapeutics, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Mee","family":"Yang","sequence":"additional","affiliation":[{"name":"SillaJen, Busan, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beodeul","family":"Kang","sequence":"additional","affiliation":[{"name":"Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Ram","family":"Kim","sequence":"additional","affiliation":[{"name":"Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6979-5812","authenticated-orcid":false,"given":"Hong Jae","family":"Chon","sequence":"additional","affiliation":[{"name":"Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9780-6155","authenticated-orcid":false,"given":"Chan","family":"Kim","sequence":"additional","affiliation":[{"name":"Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"2025100312555124000_8.2.e000857.1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.trecan.2019.12.008","article-title":"Targeting the tumor microenvironment in colorectal peritoneal metastases","volume":"6","author":"Ceelen","year":"2020","journal-title":"Trends Cancer"},{"key":"2025100312555124000_8.2.e000857.2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i34.7692"},{"key":"2025100312555124000_8.2.e000857.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2013.06.030"},{"key":"2025100312555124000_8.2.e000857.4","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-00009577-200201000-00002"},{"key":"2025100312555124000_8.2.e000857.5","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3748\/wjg.v18.i13.1470","article-title":"Immunological milieu in the peritoneal cavity at laparotomy for gastric cancer","volume":"18","author":"Yoneda","year":"2012","journal-title":"World J Gastroenterol"},{"key":"2025100312555124000_8.2.e000857.6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/14737140.2016.1224666","article-title":"The current status of immunotherapy in peritoneal carcinomatosis","volume":"16","author":"Str\u00f6hlein","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"2025100312555124000_8.2.e000857.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-017-2663-1"},{"key":"2025100312555124000_8.2.e000857.8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i39.5489"},{"key":"2025100312555124000_8.2.e000857.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2199"},{"key":"2025100312555124000_8.2.e000857.10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000480","article-title":"Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis","volume":"8","author":"Tseng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100312555124000_8.2.e000857.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2006.06.031"},{"key":"2025100312555124000_8.2.e000857.12","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0109"},{"key":"2025100312555124000_8.2.e000857.13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.trecan.2016.12.005","article-title":"Tumor-Host cell interactions in ovarian cancer: pathways to therapy failure","volume":"3","author":"Pogge von Strandmann","year":"2017","journal-title":"Trends Cancer"},{"key":"2025100312555124000_8.2.e000857.14","doi-asserted-by":"crossref","first-page":"12493","DOI":"10.3748\/wjg.v20.i35.12493","article-title":"Current treatment options for colon cancer peritoneal carcinomatosis","volume":"20","author":"Aoyagi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2025100312555124000_8.2.e000857.15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejso.2018.10.542","article-title":"HIPEC with oxaliplatin for colorectal peritoneal metastasis: the end of the road?","volume":"45","author":"Ceelen","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"2025100312555124000_8.2.e000857.16","doi-asserted-by":"crossref","unstructured":"Narasimhan V et al . Colorectal peritoneal metastases: pathogenesis, diagnosis and treatment options - an evidence-based update. ANZ J Surg 2020.","DOI":"10.1111\/ans.15796"},{"key":"2025100312555124000_8.2.e000857.17","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14572","article-title":"Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice","volume":"8","author":"Lau","year":"2017","journal-title":"Nat Commun"},{"key":"2025100312555124000_8.2.e000857.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001"},{"key":"2025100312555124000_8.2.e000857.19","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.7150\/jca.32806","article-title":"STING signaling is a potential immunotherapeutic target in colorectal cancer","volume":"10","author":"Chon","year":"2019","journal-title":"J Cancer"},{"key":"2025100312555124000_8.2.e000857.20","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp Mol Med"},{"key":"2025100312555124000_8.2.e000857.21","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"2025100312555124000_8.2.e000857.22","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.160"},{"key":"2025100312555124000_8.2.e000857.23","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14754","article-title":"Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"key":"2025100312555124000_8.2.e000857.24","article-title":"Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma","author":"Kim","year":"2020","journal-title":"J Hepatol"},{"key":"2025100312555124000_8.2.e000857.25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1655"},{"key":"2025100312555124000_8.2.e000857.26","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2287"},{"key":"2025100312555124000_8.2.e000857.27","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663"},{"key":"2025100312555124000_8.2.e000857.28","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol Cancer"},{"key":"2025100312555124000_8.2.e000857.29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ebiom.2016.06.046","article-title":"Oncolytic viruses: therapeutics with an identity crisis","volume":"9","author":"Breitbach","year":"2016","journal-title":"EBioMedicine"},{"key":"2025100312555124000_8.2.e000857.30","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32325"},{"key":"2025100312555124000_8.2.e000857.31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-virology-031413-085442","article-title":"Oncolytic poxviruses","volume":"1","author":"Chan","year":"2014","journal-title":"Annu Rev Virol"},{"key":"2025100312555124000_8.2.e000857.32","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00155","article-title":"Immunotherapeutic potential of oncolytic vaccinia virus","volume":"4","author":"Thorne","year":"2014","journal-title":"Front Oncol"},{"key":"2025100312555124000_8.2.e000857.33","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3089"},{"key":"2025100312555124000_8.2.e000857.34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/OV.S59640","article-title":"The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)","volume":"4","author":"Breitbach","year":"2015","journal-title":"Oncolytic Virother"},{"key":"2025100312555124000_8.2.e000857.35","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jhep.2013.05.006","article-title":"Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?","volume":"59","author":"Hernandez-Gea","year":"2013","journal-title":"J Hepatol"},{"key":"2025100312555124000_8.2.e000857.36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1932"},{"key":"2025100312555124000_8.2.e000857.37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2687"},{"key":"2025100312555124000_8.2.e000857.38","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.183"},{"key":"2025100312555124000_8.2.e000857.39","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1172\/JCI125413","article-title":"STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade","volume":"129","author":"Yang","year":"2019","journal-title":"J Clin Invest"},{"key":"2025100312555124000_8.2.e000857.40","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.26"},{"key":"2025100312555124000_8.2.e000857.41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1142"},{"key":"2025100312555124000_8.2.e000857.42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cellimm.2015.12.003","article-title":"Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells","volume":"300","author":"Liu","year":"2016","journal-title":"Cell Immunol"},{"key":"2025100312555124000_8.2.e000857.43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5306\/wjco.v10.i2.52","article-title":"Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy","volume":"10","author":"Kanat","year":"2019","journal-title":"World J Clin Oncol"},{"key":"2025100312555124000_8.2.e000857.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.12.010"},{"key":"2025100312555124000_8.2.e000857.45","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0968-T"},{"key":"2025100312555124000_8.2.e000857.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.10.018"},{"key":"2025100312555124000_8.2.e000857.47","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.51"},{"key":"2025100312555124000_8.2.e000857.48","doi-asserted-by":"publisher","DOI":"10.1038\/nature21724"},{"key":"2025100312555124000_8.2.e000857.49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0981"},{"key":"2025100312555124000_8.2.e000857.50","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.immuni.2017.04.015","article-title":"CD4+ T cell activation and vascular normalization: two sides of the same coin?","volume":"46","author":"De Palma","year":"2017","journal-title":"Immunity"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-000857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:56:02Z","timestamp":1759521362000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-000857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,11,16]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/jitc-2020-000857"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-000857","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}